Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18251784rdf:typepubmed:Citationlld:pubmed
pubmed-article:18251784lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C0242647lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C1335512lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C1517925lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:18251784lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:18251784pubmed:issue3lld:pubmed
pubmed-article:18251784pubmed:dateCreated2008-2-6lld:pubmed
pubmed-article:18251784pubmed:abstractTextPrimary mucosa-associated lymphoid tissue (MALT) lymphoma of the prostate is rare, and only five cases have been reported. Reported herein is a new case that has involved a 9 year follow up. A 79-year-old man was treated with transurethral resection (TUR) for a mass of the right prostatic lobe, and followed up under a diagnosis of benign prostatic hyperplasia with atypical lymphoid infiltration. Seven years later TUR was again performed for a right lobe mass. The lesion was diagnosed as a relapsed MALT lymphoma after detailed histological and immunoglobulin heavy chain gene analyses of the initial and relapsed lesions. Interestingly, lymphoepithelial lesions were observed only infrequently in this tumor. The API2-MALT1 fusion, a gene alteration specific to MALT lymphoma, was absent. The patient had stage IA disease at the time of tumor relapse, and has been alive and well for the 2 years after the second TUR. The present case suggests that despite tumor recurrence, prostatic MALT lymphoma is indolent, and function-preserving therapy is warranted.lld:pubmed
pubmed-article:18251784pubmed:languageenglld:pubmed
pubmed-article:18251784pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18251784pubmed:citationSubsetIMlld:pubmed
pubmed-article:18251784pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18251784pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18251784pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18251784pubmed:statusMEDLINElld:pubmed
pubmed-article:18251784pubmed:monthMarlld:pubmed
pubmed-article:18251784pubmed:issn1440-1827lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:UedaRyuzoRlld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:EimotoTadaaki...lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:KomatsuHiroka...lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:LiChunmeiClld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:InagakiHirosh...lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:HibinoMitsuno...lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:SakumaHidenor...lld:pubmed
pubmed-article:18251784pubmed:authorpubmed-author:SakakuraTakes...lld:pubmed
pubmed-article:18251784pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18251784pubmed:volume58lld:pubmed
pubmed-article:18251784pubmed:ownerNLMlld:pubmed
pubmed-article:18251784pubmed:authorsCompleteYlld:pubmed
pubmed-article:18251784pubmed:pagination191-5lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:meshHeadingpubmed-meshheading:18251784...lld:pubmed
pubmed-article:18251784pubmed:year2008lld:pubmed
pubmed-article:18251784pubmed:articleTitlePrimary mucosa-associated lymphoid tissue lymphoma of the prostate: tumor relapse 7 years after local therapy.lld:pubmed
pubmed-article:18251784pubmed:affiliationDepartment of Pathology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.lld:pubmed
pubmed-article:18251784pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18251784pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:18251784pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18251784lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18251784lld:pubmed